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 Background 
 C-reactive protein (CRP) is a strong acute-phase reac-
tant. Elevated levels of serum CRP are found in up to 
three quarters of patients with acute ischemic stroke and 
are associated with poor outcome  [1–6] . This leads to in-
terest in the use of CRP as a biomarker of prognosis of 
ischemic stroke. Moreover, CRP may contribute to sec-
ondary brain damage after focal cerebral ischemia, pos-
sibly via a complement-mediated exacerbation of tissue 
injury  [7] .
 The CRP concentrations are under genetic influence. 
Family and twin studies found that additive genetic fac-
tors account for 27–40% of the variance in CRP, indicat-
ing a role of DNA sequence variation in determining se-
rum protein levels  [8] . Furthermore, there is accumulat-
ing evidence for an association between single nucleotide 
polymorphisms (SNPs) in the CRP gene and levels of 
CRP  [9, 10] .
 This led us to hypothesize that levels of CRP in the 
acute phase of ischemic stroke are under genetic influ-
ence as well, and that haplotypes associated with higher 
CRP levels are associated with an increased risk of poor 
outcome after acute ischemic stroke.
 Only limited and inconsistent data are available on the 
association between SNPs in the CRP gene and CRP con-
centrations in patients with acute ischemic stroke  [3, 11] .
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 Abstract 
 Background and Purpose: Elevated levels of C-reactive pro-
tein (CRP) are found in up to three quarters of patients with 
acute ischemic stroke and are associated with poor outcome. 
We investigated whether haplotypes representing common 
variations in the CRP gene are associated with levels of CRP 
in patients with acute ischemic stroke.  Methods: We includ-
ed 185 patients with ischemic stroke in whom CRP was mea-
sured within 24 h of symptom onset. Common haplotypes 
within the CRP gene were determined by 3 genotype-tag-
ging single-nucleotide polymorphisms (SNPs).  Results: Four 
haplotypes with frequencies  1 5% covered 99.2% of the ge-
netic variation. Haplotype 4 (CCG, frequency 8.3%) was
associated with a 20.6 mg/l (95% CI, 9.8–30.4) stronger in-
crease in CRP level as compared with haplotype 1 (CTC, fre-
quency 33.7%).  Conclusion: Variation in the CRP gene is
associated with levels of CRP in acute ischemic stroke. 
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 In the present study, we investigated whether haplo-
types representing common variations in the CRP gene 
are associated with levels of CRP in patients with acute 
ischemic stroke.
 Methods 
 Study Population 
 Patients were derived from the Erasmus Stroke Study, a project 
aimed at collecting clinical information, blood samples and DNA 
of all patients with neurovascular diseases admitted to Erasmus 
University Medical Center. 
 For the present study, we evaluated all patients with ischemic 
stroke admitted between December 2005 and December 2008
in whom venous blood was collected within 24 h of symptom
onset. 
 Written informed consent was obtained from all patients, 
signed by the participants or a first-degree relative, as approved 
by the Institutional Ethics Committee.
 Baseline Characteristics 
 Baseline clinical information was extracted from the trial re-
cords. This included a quantification of stroke severity according 
to the National Institutes of Health Stroke Scale (NIHSS)  [12] , 
ischemic stroke subtype according to the TOAST classification 
 [13] , and cardiovascular risk factors. 
 Measurement of CRP 
 CRP levels were determined by means of the Roche Modular 
Assay. The range of measurement is 1–285 mg/l with a variation 
coefficient of 4.6%.
 CRP Polymorphism Genotyping 
 In the Seattle SNPs program for Genomic applications, 31 
SNPs were identified in the CRP gene on chromosome 1q21 
(http://www.pga.gs.washington.edu/data/crp, ‘visual haplotype’ 
option).
 In 23 unrelated individuals of European descent, these SNPs 
formed 4 well-defined haplotypes with frequencies of more than 
5%. By selecting 3 tagging SNPs, the total common variation in 
the CRP gene is described. We selected the following tagging 
SNPs: 1184 C  1 T (rs1130864), 2042 C  1 T (rs1205) and 2911 C  1 
G (rs3093068).
 DNA was extracted according to standard procedures and 
stored at –20 ° C. Genotypes were determined in genomic DNA of 
2 ng with the Taqman allelic discrimination assay (Applied Bio-
systems, Foster City, Calif., USA) and end-point readings of fluo-
rescence were performed on Taqman Prism 7900HT (Applied 
Biosystems).
 Statistical Analysis 
 SNPs were tested for Hardy-Weinberg equilibrium with a   2 
test. The association between CRP haplotypes and levels of CRP 
were assessed with the non-parametric haplo.score function of 
Haplo Stats (http://cran-r.project.org/scr/contrib/Descriptions/
haplostats). We adjusted for age, sex and stroke severity on admis-
sion by means of multiple linear regression.
 Results 
 Between December 2005 and December 2008, 561 pa-
tients with ischemic stroke were included in the Erasmus 
Stroke Study. Of these patients, 376 were excluded for the 
present study because of CRP measurement was not ac-
complished within 24 h of stroke onset (n = 140), DNA 
was not available (226) or genotyping failed for 2 or 3 out 
of 3 SNPs (n = 10).
 In the total study population, the mean age was 64 (SD 
15), 53% were male and the median NIHSS score was 4 
(range 0–22) ( table 1 ). Mean CRP level was 10 mg/l (SD 
27). Median time from onset of symptoms to CRP mea-
surement was approximately 7 h.
Table 1. Clinical characteristics of the patients (n=185)
Demographics
Age, years
Sex, male, n (%)
64815
98 (53)
Cardiovascular risk factors
Hypertension, n (%)
Atrial fibrillation, n (%)
Diabetes mellitus, n (%)
Current cigarette smoking, n (%)
Hypercholesterolemia, n (%)
98 (53)
22 (12)
29 (16)
35 (19)
85 (46)
Medical history
Previous stroke, n (%)
Previous myocardial infarction, n (%)
Peripheral vascular disease, n (%)
50 (27)
31 (17)
13 (7)
Stroke subtype*
Large vessel disease, ≥50% stenosis, n (%)
Cardiac source of embolism, n (%)
Small vessel occlusion, n (%)
Other determined etiology, n (%)
Undetermined/negative evaluation, n (%)
28 (15) 
30 (16)
27 (15)
21 (11)
79 (43)
Stroke severity
Median (range) NIHSS score$ 4 (0–22)
Physical examination
Systolic blood pressure on admission 167834
Diastolic blood pressure on admission 86820
Laboratory assessments
Median (IQR) time from stroke onset to 
measurement of CRP, h (range) 6.6 (3–13.9)
Treatment
Treatment with rt-PA, n (%) 36 (19)
* Based on the Trial of ORG 10172 in Acute Stroke Therapy 
(TOAST) criteria [13]. 
$ Scores on the National Institutes of Health Stroke Scale
(NIHSS) [12].
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 All SNPs were in Hardy-Weinberg equilibrium. The 
1,184T-allele was present in 25.9%, the 2,042T-allele was 
present in 34.5% and the 2911G-allele in 8.6% of 370 chro-
mosomes.
 Four common haplotypes were identified ( table 2 ). 
The remaining haplotypes (CTG, TCG, TTC) were pres-
ent in less than 5%.
 Haplotype 4 (CCG) was associated with a significant 
stronger increase in CRP level (20.6 mg/l; 95% CI, 9.8–
30.4) relative to the reference haplotype 1 (CTC) ( table 2 
and  fig. 1 ). Adjustment for age, sex and NIHSS score did 
not attenuate this association ( fig. 1 ).
 Discussion 
 In this study, we found that SNPs in the CRP gene were 
associated with levels of CRP within 24 h of ischemic 
stroke onset. Haplotype 4 (CCG) was associated with sig-
nificant higher levels of CRP than haplotype 1 (CTC).
 Our results provide further proof that, apart from en-
vironmental factors, genetic variations may influence 
levels of CRP. Several studies found an association be-
tween CRP haplotypes and levels of CRP in diseases in 
which inflammation is involved  [9, 14, 15] . The direction 
of the haplotype-CRP level associations are also support-
ed by previous studies that have used the same polymor-
phisms to reconstruct the haplotypes  [9, 14, 15] . Two pre-
vious studies that investigated the association between 
SNPs in the CRP gene and levels of CRP in patients with 
acute ischemic stroke cannot be compared directly with 
ours, because only single SNPs were studied  [3, 11] . 
 The present study has some limitations. First, the study 
compromised a small number of patients. As a result, the 
precision of our estimates is limited. Furthermore, because 
of this small number of patients we could not adjust the 
association between CRP haplotypes and levels of CRP for 
vascular risk factors, like diabetes mellitus and smoking, 
which might have influenced the levels of CRP. Second, 
our results did not include information about ethnicity. 
Allele frequencies have been reported to differ between 
ethnic groups. However, the haplotype structures are sim-
ilar and therefore the direction and size of changes in CRP 
levels associated with most SNPs might be similar regard-
less of ethnic group  [15] .
 A third issue that warrants consideration in this study 
is that DNA was lacking for 226 patients who were admit-
ted within 24 h of symptom onset. On the other hand, 
comparison of the excluded patients with the study pop-
ulation showed no significant differences with regard to 
baseline characteristics or case fatality. Hence, it is not 
likely that it has substantially influenced the results.  
 Finally, our study focused on CRP levels within 24 h 
of stroke onset. As CRP may peak several days after isch-
emic stroke, CRP measured at later time points than in 
our study may better reflect the magnitude of the inflam-
matory reaction. Furthermore, we did not have levels of 
CRP prior to ischemic stroke or several months after the 
stroke. It would be interesting to compare the association 
between CRP haplotypes and these levels with that of 
stroke-free participants. On the other hand, a previous 
study did not find an association between CRP genotypes 
and baseline levels of CRP nor between CRP genotypes 
and levels of CRP in stroke-free participants  [10] .
 Increases in CRP levels following ischemic stroke may 
reflect a systemic inflammatory response, the extent of 
tissue injury, or concurrent infections. Interestingly, in 
animal models of focal cerebral ischemia, CRP increased 
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 Fig. 1. Relative effects of CRP gene haplotypes on levels of CRP 
(mg/l).  * p  ! 0.01. Regression coefficients were adjusted for age, 
sex and NIHSS score on admission. Coefficients reflect the mean 
difference in levels of CRP relative to haplotype 1 (CTC). 
Table 2. Frequency of haplotypes and association between CRP 
haplotypes and levels of CRP
Haplotype Haplotype frequency, % Haplo score p value*
1 (CTC) 33.7 –0.75 0.45
2 (CCC) 31.7 –0.01 0.98
3 (TCC) 25.5 0.41 0.68
4 (CCG) 8.3 4.49 <0.01
* p values were obtained using haplo score, after 2,377 simula-
tions. The frequencies refer to the reference (Seattle) population.
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secondary brain damage through activation of the com-
plement system  [7, 16] . These findings suggest that under-
standing genotype-phenotype associations of  CRP  poly-
morphisms may provide a genetic basis for the future de-
velopment of tailored therapeutic strategies in ischemic 
stroke.
 In conclusion, variation in the CRP gene is associated 
with levels of CRP in acute ischemic stroke. Further stud-
ies are needed to investigate the relation between varia-
tion in the CRP gene, levels of CRP and clinical outcome 
after acute ischemic stroke.
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